Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Cantargia AB
Augusta University
Augusta University
Masonic Cancer Center, University of Minnesota
University of Arizona